Latex Allergy: Avoidance First, Investigational SLIT Second, No FDA Immunotherapy
Natural rubber latex (NRL) allergy management in the US is fundamentally avoidance-based — powder-free, low-protein nitrile or neoprene gloves plus latex-safe perioperative protocols for spina bifida patients from birth — because no FDA-approved latex immunotherapy exists. Healthcare workers face 8–12% historical sensitization rates (NIOSH 1997); spina bifida patients face 10–73% sensitization (Kelly 1994 JACI 94:53).
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Latexis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Latex Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to latex — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of latex allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of latex immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of latex extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for latex allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing latex extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription latex immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat latex allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Latex?
The biology, taxonomy, and clinical fingerprint of Latex — the foundation of how SCIT targets it.
Natural rubber latex products — medical gloves, balloons, catheters, condoms — are the primary sensitization route. NIOSH-era powder-free glove mandates reduced US healthcare-worker sensitization by nearly 80% from peak levels.
- Scientific name
- Hevea brasiliensis
- Family
- EuphorbiaceaeSpurge family (rubber tree)
- Type
- Occupational/iatrogenic protein allergen (cytoplasmic exudate of rubber tree; Type I IgE-mediated; distinct from Type IV chemical dermatitis)
- Native to
- Amazon basin; commercial plantations in Southeast Asia (Malaysia, Thailand, Indonesia) and Africa; US has no significant latex tree production
- Allergen proteins
- Hev b 1 — Rubber elongation factor (14.6 kDa; major in spina bifida ~81% and HCWs ~52%; marker for SB/intraoperative sensitization per Czuppon 1993 JACI 92:690)Hev b 3 — Small rubber particle protein (24 kDa; major in spina bifida)Hev b 5 — Acidic protein (16 kDa; major in HCWs ~92% and SB ~56% per Slater 1996 J Biol Chem 271:25394)Hev b 6.01 — Prohevein (20 kDa; major in HCWs ~70%)Hev b 6.02 — Hevein (4.7 kDa; major in HCWs; main IgE epitope; drives latex-fruit syndrome via class I chitinase cross-reactivity)Hev b 11 — Class I chitinase (30 kDa; cross-reactive with fruit chitinases: banana, avocado, chestnut)Hev b 8 — Profilin (14 kDa; pan-allergen; usually clinically silent)
- Particle size
- Protein in airborne glove powder (adsorbed NRL proteins); contact via mucocutaneous, parenteral, and respiratory routes
- Avoidance difficulty
- Easy
How Latex Allergy Presents
Symptoms by body system — useful for distinguishing Latex sensitivity from overlapping allergies and infections.
Dermal (Contact — Type I IgE-mediated)
- Urticaria at glove contact sites within minutes of NRL exposure
- Angioedema of hands, wrists, face after glove or balloon contact
- Contact urticaria distinguishable from Type IV accelerator dermatitis by timing (<1 hr vs >24 hr)
- Perioral angioedema after dental work with latex gloves
Systemic (Anaphylaxis — especially perioperative)
- Generalized urticaria during surgical, dental, or diagnostic procedures with NRL equipment
- Hypotension and cardiovascular collapse during intraoperative bladder/peritoneal contact
- Throat tightness and bronchospasm from aerosolized glove powder
- Loss of consciousness in severe intraoperative anaphylaxis
- Oral allergy syndrome from latex-fruit cross-reactive foods (banana, avocado, kiwi, chestnut)
Respiratory
- Rhinitis and conjunctivitis from aerosolized NRL glove powder in healthcare settings
- Asthma exacerbation in HCW with occupational NRL sensitization
- Laryngeal edema in severe anaphylaxis
Ocular
- Conjunctival injection and tearing from aerosolized NRL in healthcare environments
- Periorbital angioedema from facial latex contact
- Allergic conjunctivitis in occupationally sensitized HCWs
Latex management in the US in 2026 is fundamentally avoidance plus engineering — powder-free, low-protein nitrile or neoprene gloves, latex-safe ORs for spina bifida patients from birth, and the NIOSH-era controls that dropped healthcare-worker sensitization by 80 percent. There is no FDA-approved latex immunotherapy; the European SLIT trials show modest benefit, but I'm not going to push an investigational therapy when avoidance works this well.
Where Latex Triggers Year-Round
Latex is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round exposure via healthcare, dental, and consumer products; no seasonal variation· Perennial exposure risk in healthcare and laboratory settings; exposure at any medical or dental encounter
US Exposure Map
10 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Moderate
- MT:
- Low
- ND:
- Low
- MN:
- Moderate
- WI:
- Moderate
- MI:
- High
- NY:
- High
- MA:
- Moderate
- OR:
- Moderate
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- None
- IL:
- High
- IN:
- Moderate
- OH:
- High
- PA:
- High
- NJ:
- Moderate
- CT:
- Low
- RI:
- Low
- CA:
- High
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- Low
- MO:
- Moderate
- KY:
- Low
- WV:
- Low
- VA:
- Moderate
- MD:
- Low
- DE:
- Low
- AZ:
- Moderate
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Moderate
- NC:
- High
- SC:
- None
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Low
What Latex Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Natural rubber latex allergen Hev b 6.02 (hevein) shares hevein-like N-terminal domain homology with class I chitinases in plant foods, producing the latex-fruit syndrome — the most clinically significant cross-reactivity in occupational allergy.
Hev b 6.02 hevein ↔ banana class I chitinase with hevein-like domain; one of the Big Four latex-fruit foods per Blanco 1994 Ann Allergy 73:309
Hev b 6.02 ↔ avocado class I chitinase; confirmed by Chen 1998 JACI 102:476; Big Four latex-fruit food
Hev b 6.02 ↔ kiwi class I chitinase; major latex-fruit-syndrome food per Blanco 1994
Hev b 6.02 ↔ chestnut class I chitinase; Big Four latex-fruit food; anaphylaxis risk higher with chestnut than with banana or avocado
Secondary latex-fruit association via Hev b class I chitinase homology (Blanco 1994)
Secondary latex-fruit association; Hev b 7 ↔ patatin-like proteins (Wagner 2002 Biochem Soc Trans 30:935)
Latex-Fruit Syndrome
Thirty to fifty percent of NRL-allergic patients develop cross-reactive food allergy via Hev b 6.02 hevein cross-reactivity with plant class I chitinases, producing oral allergy syndrome or, with the Big Four foods, full systemic reactions including anaphylaxis. Patients with confirmed latex allergy should be counseled to avoid banana, avocado, kiwi, and chestnut.
Is SCIT Right for Your Latex Allergy?
Answer 5 questions to understand your latex sensitization risk profile and whether avoidance engineering, food counseling, or allergist evaluation is most urgently needed.
Have you ever had a reaction during a medical, dental, or surgical procedure or with latex gloves?
The Latex SCIT Protocol
No FDA-approved latex immunotherapy exists in the US — management is tiered avoidance and engineering controls, with investigational SLIT available only in clinical trial settings outside the US.
Strict avoidance of all NRL products: switch to powder-free nitrile, neoprene, or vinyl gloves in all healthcare and occupational settings; avoid NRL balloons, condoms, and consumer rubber products. Latex-safe perioperative protocols for all confirmed latex-allergic patients AND all spina bifida patients from birth (Blumchen 2010 Allergy 65:1585; Cremer 1998). NIOSH 1997 Alert (DHHS Publication No. 97-135) mandates powder-free, low-protein NRL gloves in healthcare. Epinephrine auto-injector for all confirmed systemic reactors. Medical alert identification bracelet recommended.
Investigational SLIT trials (Patriarca 2002 Anesth Analg 95:956; Nettis 2007 Br J Dermatol 156:674; Lasa Luaces 2012 Ann Allergy Asthma Immunol 108:367; Bernardini 2015) show modest efficacy and acceptable tolerability for the build-up phase. SLIT shows reduced systemic risk compared to SCIT (Sastre 2003 JACI 111:985 — SCIT showed 5.7% systemic reaction rate with modest efficacy). Neither SLIT nor SCIT is FDA-approved; current AAAAI practice parameters do not endorse latex IT as standard of care (Cox 2011 JACI 127 suppl:S1). Not a clinical option in the US in 2026.
All latex-allergic patients with documented systemic reaction should carry two epinephrine auto-injectors at all times and wear medical alert identification. Prior to any procedure, inform all healthcare providers of latex allergy — including dental, radiologic, and outpatient procedures where NRL products may be used. Ensure the procedure center has a confirmed latex-safe protocol before scheduling.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Latex SCIT
No FDA-approved latex immunotherapy exists in the US with demonstrated clinical efficacy for preventing systemic reactions or inducing tolerance; the published investigational data is from European SLIT and SCIT trials with modest and inconsistent results.
- Reduction in healthcare-worker sensitization after NIOSH-era powder-free glove controls80%Allmers 2004, JACI 114:347 — 'incidence of suspected cases decreased by 79.9%' from 1998 peak; Liss 2001 Am J Ind Med 40:347 (US parallel)
- Reduction in spina bifida sensitization with latex-safe-from-birth cohorts74%Blumchen 2010, Allergy 65:1585 — latex-safe-from-birth reduced sensitization from historical 26–73% to <10%
- Investigational SCIT modest efficacy (with 5.7% systemic reaction safety concern)40%Sastre 2003, JACI 111:985 — improvement in cutaneous response and glove-wear test; 5.7% immediate systemic-reaction rate
The most efficacious intervention for latex allergy is avoidance engineering — NIOSH-era powder-free glove mandates reduced US healthcare-worker sensitization by nearly 80% from peak levels (Allmers 2004) — not immunotherapy. Investigational SLIT shows modest clinical improvement with better tolerability than SCIT but is not FDA-approved and is not standard of care per AAAAI Practice Parameters.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Latex SCIT Side Effects
Because no FDA-approved latex immunotherapy exists in the US, side-effect data for latex IT comes from European investigational trials. The SCIT trial had a 5.7% immediate systemic-reaction rate (Sastre 2003), which was the primary safety concern that has shifted interest toward investigational SLIT.
Local reactions
2 documented| Reaction | Rate | Severity |
|---|---|---|
Contact urticaria from NRL exposure (not immunotherapy) Managed by eliminating NRL glove exposure | Rate Common in sensitized HCWs | Moderate |
Type IV accelerator dermatitis (distinct from Type I IgE allergy) Managed by switching to non-accelerator nitrile gloves or vinyl; does not require IT | Rate Common — caused by thiurams, carbamates | Mild |
Systemic reactions
2 documented| Reaction | Rate | Severity |
|---|---|---|
Perioperative anaphylaxis (the primary clinical risk) If you experience throat tightness, breathing difficulty, or hypotension during any medical procedure, inform clinical staff immediately — anaphylaxis requires epinephrine and emergency care. Confirm latex-safe protocols at ALL procedure sites before scheduling. | Rate Reduced dramatically with latex-safe protocols | Severe |
Aerosolized glove powder respiratory reaction (HCW occupational exposure) | Rate Reduced substantially with powder-free glove mandates | Moderate |
Latex-safe perioperative protocols — latex-free gloves, equipment, and products for known latex-allergic patients and ALL spina bifida patients from birth — are the most effective safety intervention and have reduced latex-related fatalities substantially since the NIOSH 1997 Alert era.
SCIT vs Alternatives for Latex
Latex allergy management is dominated by engineering and avoidance — the evidence for avoidance-based interventions (powder-free gloves, latex-safe protocols) far exceeds the evidence for investigational immunotherapy in terms of population-level safety improvement.
| Criterion | Avoidance + Eng. ControlsBest | Investigational SLIT | Investigational SCIT | Antihistamines + Topical Cs |
|---|---|---|---|---|
| Effectiveness | 80% reduction in HCW sensitization (Allmers 2004) | Modest clinical improvement; inconsistent across trials | Modest efficacy; 5.7% systemic reaction rate (Sastre 2003) | Symptomatic relief only; does not desensitize |
| Cost | Cost of nitrile gloves vs NRL — modest | Not commercially available in US | Not commercially available in US | Low — OTC available |
| Duration | Ongoing indefinitely | 6 months to years (European trial protocols) | 14-week cluster build-up in Sastre 2003 | Ongoing per exposure |
| Convenience | Requires consistent protocol enforcement | Not available in US 2026 | Not available in US; safety concern limits enthusiasm | Oral/topical, convenient |
| Safety | Highly safe; eliminates sensitization driver | Better tolerability than SCIT; still investigational | 5.7% immediate systemic reactions — safety barrier | Safe; does not address underlying allergy |
| Lasting effect | Prevents new sensitization; established sensitization persists | Uncertain long-term durability | Uncertain long-term durability | No lasting effect on sensitization |
Avoidance + Eng. ControlsBest
Investigational SLIT
Investigational SCIT
Antihistamines + Topical Cs
Avoidance engineering — powder-free nitrile gloves, latex-safe perioperative protocols, and latex-safe-from-birth for spina bifida patients — is the evidence-based cornerstone of latex allergy management. For latex-allergic patients who also have inhalant allergies from dust mite, cat, dog, or grass, Curex at-home IgE testing can identify those concurrent inhalant sensitivities as well as latex-fruit cross-reactivities (banana, avocado, kiwi, chestnut via Hev b 6.02 hevein), and Curex at-home allergy shots with pricing confirmed in a current program quote treat the inhalant comorbidities from home — allergist-directed, with a video-supervised first dose and a prescribed epinephrine auto-injector confirmed on hand — while latex management itself remains avoidance-based, since no FDA-approved latex immunotherapy exists.
What Latex SCIT Actually Costs
Latex-specific IgE testing (ImmunoCAP k82) and allergist consultation are covered under standard laboratory and allergy benefits. Component-resolved diagnostics for latex (Hev b 1, 3, 5, 6.01, 6.02) may require specialized lab authorization. No immunotherapy is billable because no FDA-licensed latex IT product exists. Occupational health benefits may cover surveillance testing for HCWs and worksite PPE.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your latex allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Latex SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
No. There is no FDA-approved latex immunotherapy — neither subcutaneous (SCIT) nor sublingual (SLIT) — in the US as of 2026 (FDA CBER Allergenics list; Cox 2011 JACI 127 suppl:S1). The Sastre 2003 DBPC SCIT trial in 24 NRL-allergic workers showed modest efficacy but a 5.7% immediate systemic-reaction rate, which raised safety concerns that have limited further SCIT development. Investigational SLIT trials (Patriarca 2002; Nettis 2007; Lasa Luaces 2012; Bernardini 2015) show better tolerability and modest clinical improvement, but none of these are FDA-approved or endorsed as standard of care by AAAAI Practice Parameters. The most effective intervention for latex allergy is avoidance engineering — primarily switching to powder-free nitrile or neoprene gloves.
Latex-fruit syndrome is the cross-reactive food allergy affecting 30–50% of NRL-allergic patients (Blanco 1994 Ann Allergy 73:309). The molecular mechanism is homology between Hev b 6.02 (hevein, a 4.7 kDa latex protein) and class I chitinases with hevein-like N-terminal domains in plant foods (Diaz-Perales 1999 JACI 104:681). The primary associated foods — the Big Four — are banana, avocado, kiwi, and chestnut. Secondary associations include papaya, fig, pineapple, peach, tomato, and bell pepper via related cross-reactive proteins. Clinical reactions range from oral allergy syndrome (mouth tingling, pruritis) to full systemic anaphylaxis — chestnut in particular carries high anaphylaxis risk. All latex-allergic patients should be counseled to avoid the Big Four foods and to carry epinephrine if reactions have included systemic symptoms.
Two populations have the highest historical latex sensitization rates. Healthcare workers who used powdered latex gloves prior to NIOSH 1997 Alert implementation showed 8–12% sensitization (NIOSH 1997 DHHS Publication No. 97-135), with some series reaching 17% (Allmers 1998 JACI 102:841). Spina bifida patients — who undergo multiple urologic and surgical procedures from birth with extensive mucosal NRL contact — showed sensitization rates from 10% to 73%, depending on the cohort (Kelly 1994 JACI 94:53 — 73.3%; Niggemann 1998 JACI 102:665 — 55.3%). After NIOSH-era latex-safe protocols and powder-free glove mandates, US healthcare-worker sensitization declined by nearly 80% from peak levels (Allmers 2004 JACI 114:347). Spina bifida sensitization has also declined dramatically with latex-safe-from-birth cohorts to <10% (Blumchen 2010 Allergy 65:1585).
There are two distinct types of skin reactions to NRL products: Type I (IgE-mediated, true latex allergy) and Type IV (delayed-type contact dermatitis, caused by chemical accelerators, not NRL proteins). Type I latex allergy is an IgE-mediated hypersensitivity to NRL proteins (Hev b 1, 3, 5, 6.01, 6.02, etc.) that presents within minutes as contact urticaria, angioedema, or anaphylaxis. Type IV contact dermatitis is caused by rubber chemical accelerators — thiurams, carbamates, mercaptobenzothiazole — added during glove manufacturing, presents as a delayed (>24 hour) eczematous dermatitis, and is NOT IgE-mediated. Type IV dermatitis is managed by switching to accelerator-free nitrile gloves or vinyl; it does not require allergy evaluation and does not carry anaphylaxis risk. The distinction is critical for clinical management — only Type I allergy requires epinephrine prescription and latex-safe protocols.
Yes — latex-safe from birth is the standard of care for all spina bifida patients, regardless of prior allergy history. The historical sensitization rate in spina bifida cohorts was 10–73% (Kelly 1994 JACI 94:53; Niggemann 1998 JACI 102:665), driven by repeated mucosal NRL contact during urologic catheterizations, bladder surgeries, and other procedures from infancy. Latex-safe-from-birth cohorts — where NRL is eliminated from all procedures starting at birth — show sensitization rates below 10% (Blumchen 2010 Allergy 65:1585; Cremer 1998), demonstrating that primary prevention is highly effective. All care centers for spina bifida patients — hospitals, clinics, schools — should maintain latex-safe environments, and parents should inform all providers at every encounter.
US allergists use serum-specific IgE to NRL (ImmunoCAP k82) as the primary diagnostic screen because latex skin-prick testing extract is not FDA-licensed for diagnostic use in the US. Curex offers this at-home IgE testing as a convenient first-line screen, and a positive result is reviewed with a board-certified allergist. Component-resolved diagnostics distinguish the two major sensitization patterns: Hev b 1 and Hev b 3 positivity (spina bifida / intraoperative sensitization pattern) versus Hev b 5, Hev b 6.01, and Hev b 6.02 positivity (healthcare worker / airway/skin sensitization pattern). Hev b 6.02 (hevein) identifies patients at high risk for latex-fruit syndrome. Provocation testing — the glove-wear test or mucosal challenge — is the gold standard when sIgE is equivocal (Niggemann 1998 JACI 102:665) but carries systemic reaction risk and should only be performed in a supervised clinical setting with emergency equipment available.
Vinyl (polyvinyl chloride) gloves are latex-free and generally safe for latex-allergic individuals. Nitrile gloves are typically the preferred substitute for clinical and food-service use because they offer better puncture resistance and tactile sensitivity than vinyl. Neoprene gloves are another latex-free option. Vinyl gloves are acceptable for low-risk applications where durability is less critical. Key caution: verify that 'latex-free' labeling is accurate — some household rubber products labeled 'synthetic rubber' may contain NRL proteins. For high-risk applications (surgery, invasive procedures), only FDA-cleared latex-free medical gloves from confirmed NRL-free manufacturers should be used. Type IV accelerator dermatitis patients — who do not have IgE latex allergy — may also benefit from switching to accelerator-free nitrile gloves specifically, as standard nitrile may still contain thiurams.
Yes — at every appointment and for every new dental provider. Dental offices routinely use latex products including gloves, rubber dams, orthodontic elastics, and some anesthetic cartridge stoppers. Perioperative dental anaphylaxis from latex is a documented risk, particularly during procedures involving mucosal contact with NRL products. Before your appointment, confirm explicitly that your dental provider will use a latex-safe protocol — nitrile or vinyl gloves, non-latex rubber dam alternatives, and latex-free equipment throughout the procedure. Scheduling your appointment as the first of the day reduces residual airborne NRL protein from previous procedures. Carry your epinephrine auto-injector to all dental appointments and inform both the dentist and dental assistant before any procedure begins.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.